Literature DB >> 18242185

Proteasome inhibitor MG132 blocks viral DNA replication and assembly of human cytomegalovirus.

Marion Kaspari1, Nina Tavalai, Thomas Stamminger, Albert Zimmermann, Rita Schilf, Elke Bogner.   

Abstract

This study provides evidence that proteasomal activity is required at multiple steps in human cytomegalovirus replication. Electron microscopy revealed that no viral particles were assembled in the presence of proteasome inhibitor MG132. Immunofluorescence and Western blot analyses using MG132 demonstrated that immediate early gene expression was suppressed at low but not high MOI. In contrast, expression of late proteins was completely blocked independent of MOI. Additionally, pulsed-field gel electrophoresis demonstrated that MG132 interferes with cleavage of HCMV DNA. Bromodeoxyuridine incorporation studies showed that de novo viral DNA synthesis is reduced in the presence of MG132. Furthermore, in contrast to previous hypotheses we demonstrated that neither the ND10 components PML and hDaxx nor NFkappaB activation represent the target for MG132.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18242185     DOI: 10.1016/j.febslet.2008.01.040

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

1.  Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.

Authors:  P S Satheshkumar; Luis C Anton; Patrick Sanz; Bernard Moss
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

2.  Human cytomegalovirus UL76 elicits novel aggresome formation via interaction with S5a of the ubiquitin proteasome system.

Authors:  Shin-Rung Lin; Meei Jyh Jiang; Hung-Hsueh Wang; Cheng-Hui Hu; Ming-Shan Hsu; Edward Hsi; Chang-Yih Duh; Shang-Kwei Wang
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

Review 3.  DNA virus replication compartments.

Authors:  Melanie Schmid; Thomas Speiseder; Thomas Dobner; Ramon A Gonzalez
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

4.  Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression.

Authors:  Young-Eui Kim; Jin-Hyoung Lee; Eui Tae Kim; Hye Jin Shin; Su Yeon Gu; Hyang Sook Seol; Paul D Ling; Chan Hee Lee; Jin-Hyun Ahn
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

5.  Human cytomegalovirus IE2 86 and IE2 40 proteins differentially regulate UL84 protein expression posttranscriptionally in the absence of other viral gene products.

Authors:  Rebecca L Sanders; Deborah H Spector
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

6.  DSTP-27 prevents entry of human cytomegalovirus.

Authors:  Rebekka Paeschke; Ina Woskobojnik; Vadim Makarov; Michaela Schmidtke; Elke Bogner
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

7.  Identification of TRIM23 as a cofactor involved in the regulation of NF-kappaB by human cytomegalovirus.

Authors:  Emma Poole; Ian Groves; Andrew MacDonald; Yin Pang; Antonio Alcami; John Sinclair
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

8.  Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication.

Authors:  R van Domselaar; S A H de Poot; E B M Remmerswaal; K W Lai; I J M ten Berge; N Bovenschen
Journal:  Cell Death Differ       Date:  2012-10-26       Impact factor: 15.828

9.  Human cytomegalovirus inhibits apoptosis by proteasome-mediated degradation of Bax at endoplasmic reticulum-mitochondrion contacts.

Authors:  Aiping Zhang; Richard L Hildreth; Anamaris M Colberg-Poley
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

10.  Human cytomegalovirus infection causes premature and abnormal differentiation of human neural progenitor cells.

Authors:  Min Hua Luo; Holger Hannemann; Amit S Kulkarni; Philip H Schwartz; John M O'Dowd; Elizabeth A Fortunato
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.